SunBio,Inc.

A067370

KR7067370007

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
8,780 ^KRW	+1.86%		+9.20%	-22.30%

2021	SunBio,Inc. has filed an IPO.	CI
2019	SunBio,Inc. announced that it has received KRW 2 billion in funding	CI

SunBio,Inc. has filed an IPO.

October 27, 2021 at 12:00 am EDT

SunBio,Inc. has filed an IPO. Security Name: Shares Security Type: Common Stock PriceRange: KRW 16100 to KRW 18300 Transaction Features: Sponsor Backed Offering

Latest news about SunBio,Inc.

SunBio,Inc. has filed an IPO.	21-10-27	CI
SunBio,Inc. announced that it has received KRW 2 billion in funding	19-05-12	CI
Jeong, Lee, Kim, Chang, Han and Oh acquired 3.1% stake in SunBio,Inc. from Kangpyung Telecom Co., Ltd. for KRW 3.3 billion.	18-05-08	CI
Han, Kim and Oh acquired 0.91% stake in SunBio,Inc. from Kangpyung Telecom Co., Ltd. for approximately KRW 950 million.	18-05-08	CI
An unknown buyer acquired 0.023% stake in SunBio,Inc. from Kangpyung Telecom Co., Ltd. for KRW 31.9 million.	18-04-19	CI
An unknown individual acquired 0.56% stake in SunBio,Inc. from Kangpyung Telecom Co., Ltd. for approximately KRW 600 million.	18-04-19	CI
An unknown individual acquired 0.39% stake in SunBio,Inc. from Kangpyung Telecom Co., Ltd. for KRW 390 million.	18-04-19	CI
An unknown individual and others acquired 3.2% stake in SunBio,Inc. from Kangpyung Telecom Co., Ltd. for KRW 2.9 billion.	18-04-19	CI
SunBio,Inc. has withdrawn its IPO.	16-12-09	CI
SunBio Corporation's Equity Buyback announced on March 21, 2016 has expired.	16-09-21	CI
Tranche Update on SunBio Corporation's Equity Buyback Plan announced on March 21, 2016.	16-06-26	CI
SunBio Corporation announces an Equity Buyback for KRW 1,200 million worth of its shares.	16-03-20	CI
SunBio Corporation authorizes a Buyback Plan.	16-03-20	CI
SunBio Corporation has withdrawn its IPO.	15-11-06	CI
SunBio Corporation cancelled the acquisition of Daewoo Special Purpose Acquisition 2 Co., Ltd. in a reverse merger transaction.	15-05-18	CI
SunBio Corporation agreed to acquire Daewoo Special Purpose Acquisition 2 Co., Ltd. in a reverse merger transaction.	15-03-29	CI

SunBio,Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. The Company operates its business through three segments. The Polyethylene Glycol (PEG) Derivative Product business segment is involved in the manufacturing and sale of PEG derivative products. The PEG derivatives are intermediate materials used in dermal filler, drug delivery systems, hydrogel, and nanotechnology. The Biosimilar Business segment is involved in the manufacturing and sale of royalty and technology transfer products. The main products are neutropenia treatment products, and hepatitis C treatment products. The New Drug Development Business segment is involved in the development of oxygen carriers, artificial blood, stroke aid agents, cartilage synovial fillers, dry mouth treatment drugs, and long-term preservatives.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SUNBIO,INC.	-22.30%	78.55M
MERCK KGAA	+4.41%	70.44B
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B
YUHAN CORPORATION	+3.20%	3.85B
INDIVIOR PLC	+20.76%	2.38B
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B

Specialty & Advanced Pharmaceuticals

SunBio,Inc.

Equities

A067370

KR7067370007

Pharmaceuticals

SunBio,Inc. has filed an IPO.

Latest news about SunBio,Inc.

Chart SunBio,Inc.

Company Profile

Sector Specialty & Advanced Pharmaceuticals